Novel therapeutic agents for osteosarcoma

Kathleen O'Day, Richard Gorlick

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.

Original languageEnglish (US)
Pages (from-to)511-523
Number of pages13
JournalExpert Review of Anticancer Therapy
Volume9
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Osteosarcoma
Tumor Microenvironment
Therapeutics
Signal Transduction
Bone and Bones
Recurrence
Drug Therapy
Survival
Neoplasms

Keywords

  • Chemotherapy
  • Novel agent
  • Osteosarcoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Novel therapeutic agents for osteosarcoma. / O'Day, Kathleen; Gorlick, Richard.

In: Expert Review of Anticancer Therapy, Vol. 9, No. 4, 2009, p. 511-523.

Research output: Contribution to journalArticle

O'Day, Kathleen ; Gorlick, Richard. / Novel therapeutic agents for osteosarcoma. In: Expert Review of Anticancer Therapy. 2009 ; Vol. 9, No. 4. pp. 511-523.
@article{e6fe902ac8e942b98895b5f8bd142a98,
title = "Novel therapeutic agents for osteosarcoma",
abstract = "Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30{\%} of patients with localized disease and 80{\%} of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.",
keywords = "Chemotherapy, Novel agent, Osteosarcoma",
author = "Kathleen O'Day and Richard Gorlick",
year = "2009",
doi = "10.1586/ERA.09.7",
language = "English (US)",
volume = "9",
pages = "511--523",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Novel therapeutic agents for osteosarcoma

AU - O'Day, Kathleen

AU - Gorlick, Richard

PY - 2009

Y1 - 2009

N2 - Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.

AB - Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.

KW - Chemotherapy

KW - Novel agent

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=67650305793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650305793&partnerID=8YFLogxK

U2 - 10.1586/ERA.09.7

DO - 10.1586/ERA.09.7

M3 - Article

VL - 9

SP - 511

EP - 523

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -